Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering

Prelude Therapeutics Inc

2026-Q1 EPS reported -$0.13 vs consensus -$0.25 ▲ beat (+48.7%)

Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.
Cash, equivalents & securities of $84.8M at March 31; subsequent $90M offering extends runway to Q2 2028.
Initiated Phase 1 trial of PRT12396, mutant-selective JAK2V617F inhibitor, in PV and MF patients.
IND for KAT6A degrader PRT13722 expected by mid-2026; Phase 1 in ER+ breast cancer in 2H 2026.
Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026.

item 2.02item 7.01item 9.01

Source: SEC EDGAR

accession 0001193125-26-218162

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.